Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 04.05.2026 1 AJR Am J Roentgenol 1 Am J Respir Cell Mol Biol 1 Ann Oncol 1 Ann Surg Oncol 2 Ann Thorac Surg 5 Anticancer Res 1 Arch Bronconeumol 1 Arch Pathol Lab Med 4 BMC Cancer 1 Br J Cancer 1 Cancer Lett 2 Cancer Sci 2 Clin Cancer Res 6 Clin Lung Cancer 1 J Cancer Res Clin Oncol 1 J Clin Invest 1 J Clin Oncol 2 J Thorac Oncol 1 JAMA Oncol 4 Lung Cancer 1 Oncogene 1 PLoS Comput Biol 4 PLoS One 1 Proc Natl Acad Sci U S A 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ROSENKRANTZ AB
   April 2026: Screening DBT, Vision-Language Models, Lung Cancer Ablation, and More.
   AJR Am J Roentgenol. 2026 Apr 29:1-2. doi: 10.2214/AJR.25.33516.
   PubMed        
   
   

   
   Am J Respir Cell Mol Biol

2. GHANBAR MI, Villabona-Rueda A, Philip N, Rodriguez Ortega R, et al
   Macrophage CCL18 promotes lung inflammation in checkpoint inhibitor pneumonitis.
   Am J Respir Cell Mol Biol. 2026;74:454-465.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. MAVRIKIOS A, Bortolot M, Le Pechoux C, Remon J, et al
   Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
   Ann Oncol. 2026 Apr 28:S0923-7534(26)00159-6. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. D'SOUZA M, Andree M, Feili A, Sadr-Azodi O, et al
   Pulmonary Metastases After Surgical Resection of Pancreatic Ductal Adenocarcinoma: Impact on Long-Term Survival and Perspectives on Targeted Treatments.
   Ann Surg Oncol. 2026 Apr 27. doi: 10.1245/s10434-026-19586.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. BOSTOCK IC, Fox AH, Engelhardt KE, Huang K, et al
   Does This Lymph Node Look Bulky to You? What Should We Do About It? A Survey of Thoracic Surgeons.
   Ann Thorac Surg. 2026;121:1195-1201.
   PubMed         Abstract available
   
   
6. WATANABE Y, Uchida S, Hattori A, Fukui M, et al
   A Comparative Analysis of Nodal Spread in Solid-Predominant vs Pure-Solid Stage IA Hypometabolic Lung Adenocarcinoma.
   Ann Thorac Surg. 2026;121:1221-1229.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. NAKATANI H, Kawachi H, Yamada T, Furuya N, et al
   Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.
   Anticancer Res. 2026;46:2789-2806.
   PubMed         Abstract available
   
   
8. HASHIMOTO K, Nishimura S, Goto K
   Potential of Inflammatory and Nutritional Markers and Clinicopathological Factors for Prognostic Prediction in Osteosarcoma.
   Anticancer Res. 2026;46:2713-2723.
   PubMed         Abstract available
   
   
9. LAN D, Wei L, Liu D, Mao YA, et al
   NK92-exo Induces Ferroptosis in A549 Cells by Targeting a miR-663a-SLC11A2 Axis.
   Anticancer Res. 2026;46:2467-2485.
   PubMed         Abstract available
   
   
10. NOJIRI T, Omura A, Nishimura H, Uda H, et al
    Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study.
    Anticancer Res. 2026;46:2781-2788.
    PubMed         Abstract available
    
    
11. GULDIMANN M, El-Gedaily M, Cimander B, Belde D, et al
    Effect of Increased Image Matrix on Lung Nodule Volumetry in Chest CT: A Phantom Study.
    Anticancer Res. 2026;46:2693-2702.
    PubMed         Abstract available
    
    

    
    Arch Bronconeumol

12. CABALLEROS LAM M, Pujols Leon PR, Inarrairaegui M, Ezponda A, et al
    Comparison of Lung Cancer Screening Programs in Liver Transplant Recipients and the General Population.
    Arch Bronconeumol. 2026 Apr 9:S0300-2896(26)00124.
    PubMed         Abstract available
    
    

    
    Arch Pathol Lab Med

13. LI J, Sandhu A, Smith M, Larsen BT, et al
    The Utility of CDX2 and CK20 Immunohistochemical Reactivity to Distinguish Adenocarcinomas of the Lung From Their Benign Mimics.
    Arch Pathol Lab Med. 2025;150:360-364.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. YIN X, He X, Guo W, Lu H, et al
    Prognostic value of CALLY index in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
    BMC Cancer. 2026 Apr 24. doi: 10.1186/s12885-026-16061.
    PubMed        
    
    
15. YAMAGUCHI T, Shimizu J, Matsuzawa R, Shimomura K, et al
    Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.
    BMC Cancer. 2026 Apr 25. doi: 10.1186/s12885-026-15989.
    PubMed        
    
    
16. ZHANG M, Jiao T, Ma Y, Yang S, et al
    The dual role of baseline absolute eosinophil count in non-small cell lung cancer immunotherapy: a biomarker for enhanced efficacy and elevated risk of immune checkpoint inhibitor-related pneumonitis.
    BMC Cancer. 2026 Apr 27. doi: 10.1186/s12885-026-16104.
    PubMed        
    
    
17. CHEN S, Yu J, Zhou Q, Li L, et al
    Trends in cardiovascular disease mortality among older adults with co-occuring lung cancer in the United States from 1999 to 2020.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16010.
    PubMed        
    
    

    
    Br J Cancer

18. CHOI E, Luo S, Ding VY, Graber-Nadich A, et al
    Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.
    Br J Cancer. 2026 Apr 27. doi: 10.1038/s41416-026-03454.
    PubMed         Abstract available
    
    

    
    Cancer Lett

19. ZHANG D, Zhou L, Dai C, Peng J, et al
    Extracellular matrix stiffness orchestrates NETs formation and mTOR-Driven metabolic reprogramming in lung cancer.
    Cancer Lett. 2026;651:218537.
    PubMed         Abstract available
    
    

    
    Cancer Sci

20. LIANG Y, Ma H, Sun W, Chen Y, et al
    The Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC.
    Cancer Sci. 2026;117:1244-1259.
    PubMed         Abstract available
    
    
21. JIN Y, Zhang T, Wu Z, Liang Y, et al
    SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.
    Cancer Sci. 2026;117:1346-1361.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

22. LEE EJ, Ko JA, Kim MJ, Cho JS, et al
    JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.
    Clin Cancer Res. 2026;32:1835-1845.
    PubMed         Abstract available
    
    
23. HASHMI A, Linford J, Chauhan PS, Parikh K, et al
    Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.
    Clin Cancer Res. 2026 Apr 30. doi: 10.1158/1078-0432.CCR-25-4983.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

24. CELIKARSLAN S, Sezen D, Duman M, Durankus NK, et al
    Real-World Clinical Outcomes of Concurrent Chemotherapy and Dose-Escalated Twice-Daily Radiotherapy With Simultaneous Integrated Boost (SIB) for Limited-Stage Small Cell Lung Cancer.
    Clin Lung Cancer. 2026 Mar 26:S1525-7304(26)00043.
    PubMed         Abstract available
    
    
25. LO S, Li Y, Laden F, Kessler W, et al
    Neighborhood Socioeconomics and Lung Cancer Recurrence and Progression.
    Clin Lung Cancer. 2026 Mar 29:S1525-7304(26)00045.
    PubMed         Abstract available
    
    
26. KUMAR P, Slaven JE, Zhou T, Tran M, et al
    Prognostic Significance and Biomarker Identification by Progression Patterns in Patients With Small Cell Lung Cancer After Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2026 Apr 3:S1525-7304(26)00048.
    PubMed         Abstract available
    
    
27. LIU H, Gu Z, Yu K, Zhao ZR, et al
    Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non-Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study.
    Clin Lung Cancer. 2026 Apr 3:S1525-7304(26)00049.
    PubMed         Abstract available
    
    
28. GHADDAR F, Ahmed S, Kirsch B, Jennewein L, et al
    Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:24-28.
    PubMed         Abstract available
    
    
29. KROPF-SANCHEN C, Frost N, Kuon J, Wermke M, et al
    A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations.
    Clin Lung Cancer. 2026 Mar 18:S1525-7304(26)00039.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

30. MAEDA R, Inomata M, Hazemoto T, Yamada R, et al
    Idiopathic pulmonary fibrosis predicts local recurrence following surgery in patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2026;152:95.
    PubMed         Abstract available
    
    

    
    J Clin Invest

31. XING W, Zhou Y, Haedicke K, Wang C, et al
    Label-free streamlined photoacoustic image guidance facilitates NIR-II photoablation in models of melanoma lung metastases.
    J Clin Invest. 2026;136:e196095.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

32. SHIMIZU T, Sands J, Yoh K, Spira A, et al
    Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
    J Clin Oncol. 2026 Apr 30:JCO2600937. doi: 10.1200/JCO-26-00937.
    PubMed        
    
    

    
    J Thorac Oncol

33. KOGA T, Ogawa H, Radulovich N, Pham NA, et al
    Endobronchial Ultrasound-Guided Biopsy Derived Lung Cancer Models: A Platform for Precision Therapy.
    J Thorac Oncol. 2026 Apr 27:103893. doi: 10.1016/j.jtho.2026.103893.
    PubMed         Abstract available
    
    
34. HUANG J, Chen G, Wang Z, Jin W, et al
    Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trial.
    J Thorac Oncol. 2026 Apr 22:103737. doi: 10.1016/j.jtho.2026.103737.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

35. SOCINSKI MA, Stahel R, Lee DH, Cappuzzo F, et al
    Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.
    JAMA Oncol. 2026 Apr 30. doi: 10.1001/jamaoncol.2026.0818.
    PubMed         Abstract available
    
    

    
    Lung Cancer

36. SAIKI M, Inoue T, Takusagawa K, Homma K, et al
    Association of tumor CD73 expression with clinical outcomes in small cell lung cancer treated with first-line chemo-immunotherapy.
    Lung Cancer. 2026;216:109425.
    PubMed         Abstract available
    
    
37. ELTER T, Marschall U, Maier PM, Grellmann C, et al
    Real-world evidence of the impact of guideline concordance on survival in non-small cell lung cancer.
    Lung Cancer. 2026;216:109426.
    PubMed         Abstract available
    
    
38. SOO RA, Fernandez-Penas P, Li M, Voon PJ, et al
    Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.
    Lung Cancer. 2026;216:109405.
    PubMed         Abstract available
    
    
39. GALLAGHER TJ, Kokot NC, Lopez J, Rodriguez E, et al
    Association of cannabis use and lung cancer: a retrospective cohort study.
    Lung Cancer. 2026;216:109421.
    PubMed         Abstract available
    
    

    
    Oncogene

40. LYU Q, Liu H, Shen W, Lin Z, et al
    KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.
    Oncogene. 2026 Apr 29. doi: 10.1038/s41388-026-03798.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

41. ATITEY K, Anchang B
    PICDGI: A framework for predicting cancer driver genes through dynamic gene-gene interaction modeling of single-cell data.
    PLoS Comput Biol. 2026;22:e1014143.
    PubMed         Abstract available
    
    

    
    PLoS One

42. RUANGPRACHA A, Sae-Lee C, Chitta P, Grove H, et al
    Unraveling the role of ChREBP in lung adenocarcinoma: Expression, regulatory networks, and potential functional impact.
    PLoS One. 2026;21:e0347907.
    PubMed         Abstract available
    
    
43. 
    Retraction: High CASC expression predicts poor prognosis of lung cancer: A systematic review with meta-analysis.
    PLoS One. 2026;21:e0348041.
    PubMed        
    
    
44. VAILANKANNI N, Nagarajan B
    Deep feature optimization using fusion of multiple self-supervised learning approaches and filter-based feature selection for lung cancer histopathology classification.
    PLoS One. 2026;21:e0348194.
    PubMed         Abstract available
    
    
45. 
    Retraction: Analysis of survival for lung cancer resections cases with fuzzy and soft set theory in surgical decision making.
    PLoS One. 2026;21:e0347910.
    PubMed        
    
    

    
    Proc Natl Acad Sci U S A

46. GARRIDO A, Tamayo-Torres E, Abdo S, Durham E, et al
    The antimetastatic effects of calorie restriction are negated by voluntary exercise in an aggressive breast cancer mouse model.
    Proc Natl Acad Sci U S A. 2026;123:e2524488123.
    PubMed         Abstract available
    
    

    
    Thorax

47. MULLEN KA, Evison M
    Smoking cessation within lung cancer screening: how much more evidence is needed?
    Thorax. 2026 Apr 24:thorax-2026-224965. doi: 10.1136/thorax-2026-224965.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum